BNP Paribas Financial Markets
CRVS icon

BNP Paribas Financial Markets’s Corvus Pharmaceuticals CRVS Stock Holding History

BNP Paribas Financial Markets’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$191K Sell
12,785
-8,528
-40% -$118K ﹤0.01% 4260
2026
Q1 		$312K Buy
21,313
+14,747
+225% +$235K ﹤0.01% 3841
2025
Q4 		$50.6K Sell
6,566
-5,950
-48% -$46.9K ﹤0.01% 4680
2025
Q3 		$92.2K Buy
12,516
+6,975
+126% +$35.7K ﹤0.01% 4337
2025
Q2 		$22.2K Buy
5,541
+4,608
+494% +$16.8K ﹤0.01% 4556
2025
Q1 		$2.97K Buy
933
+72
+8% +$339 ﹤0.01% 4930
2024
Q4 		$4.61K Sell
861
-2,249
-72% -$16.8K ﹤0.01% 4941
2024
Q3 		$16.4K Buy
+3,110
New +$11.2K ﹤0.01% 3765
2023
Q1 		– Sell
-232
Closed -$197 – 3893
2022
Q4 		$197 Buy
232
+133
+134% +$118 ﹤0.01% 3927
2022
Q3 		$81 Sell
99
-1,125
-92% -$1.07K ﹤0.01% 4658
2022
Q2 		$1.21K Buy
+1,224
New +$1.5K ﹤0.01% 3898
2021
Q1 		– Sell
-4
Closed -$14 – 4028
2020
Q4 		$14 Hold
4
– – ﹤0.01% 4111
2020
Q3 		$16 Hold
4
– – ﹤0.01% 4163
2020
Q2 		$11 Sell
4
-75
-95% -$222 ﹤0.01% 4274
2020
Q1 		$167 Hold
79
– – ﹤0.01% 4192
2019
Q4 		$430 Sell
79
-1,727
-96% -$6.04K ﹤0.01% 4259
2019
Q3 		$5.44K Hold
1,806
– – ﹤0.01% 4257
2019
Q2 		$6.75K Sell
1,806
-1,337
-43% -$5.24K ﹤0.01% 4191
2019
Q1 		$12.6K Buy
3,143
+2,934
+1,404% +$12.4K ﹤0.01% 3995
2018
Q4 		$767 Sell
209
-209
-50% -$1.43K ﹤0.01% 3955
2018
Q3 		$3.59K Sell
418
-66
-14% -$660 ﹤0.01% 4160
2018
Q2 		$5.31K Sell
484
-1,225
-72% -$13.7K ﹤0.01% 4076
2018
Q1 		$19.7K Buy
1,709
+13
+0.8% +$123 ﹤0.01% 3927
2017
Q4 		$17.6K Buy
1,696
+1,126
+198% +$14.4K ﹤0.01% 3976
2017
Q3 		$9.09K Buy
570
+190
+50% +$2.63K ﹤0.01% 3895
2017
Q2 		$4.6K Buy
380
+374
+6,233% +$3.99K ﹤0.01% 4036
2017
Q1 		$125 Sell
6
-37
-86% -$580 ﹤0.01% 3990
2016
Q4 		$615 Sell
43
-182
-81% -$2.77K ﹤0.01% 4050
2016
Q3 		$3.7K Buy
225
+94
+72% +$1.35K ﹤0.01% 3427
2016
Q2 		$1.87K Buy
+131
New +$1.77K ﹤0.01% 3452

Other funds holding CRVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets's CRVS Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Corvus Pharmaceuticals (CRVS) stake by 40% in Q2 2026, selling an estimated $118K and leaving 12,785 shares worth $191K. The position accounts for ﹤0.01% of the portfolio, ranked #4260.

BNP Paribas Financial Markets first reported a position in CRVS in Q2 2016 and has held it in 30 quarters since. The position peaked at $312K in Q1 2026. 160 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • BNP Paribas Financial Markets held 12,785 shares of Corvus Pharmaceuticals worth $191K as of Q2 2026.
  • BNP Paribas Financial Markets sold 8,528 Corvus Pharmaceuticals shares in Q2 2026, an estimated $118K.
  • Corvus Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #4260 holding.
  • BNP Paribas Financial Markets first reported a position in Corvus Pharmaceuticals in Q2 2016 and has held it in 30 quarters since.
  • BNP Paribas Financial Markets's Corvus Pharmaceuticals position peaked at $312K in Q1 2026.
  • 160 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.